| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vivo |
During the second hour of a 2-hour 11 mM hyperglycemic clamp, infusion of GLP-1(7-37) (0.5, 5, or 50 pmol/min/kg) resulted in a dose-related rise in glucose-stimulated plasma insulin. Rats had improved concentration and a higher rate of glucose infusion [2]. GLP-1(7-37) (5 pmol/min/kg) was infused into rats kept at 11 mM glucose for 1 to 7 hours, increasing plasma insulin concentrations in comparison to rats given a vehicle injection. kept growing. 2].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, weighing 300 to 350 g, were administered intravenous (iv) (iv)glucose at a variable rate for 7 hrs (hrs (hours)) to maintain plasma glucose concentration at 11 mM [2].
Doses: 5 pmol/min/kg. Route of Administration: intravenous (iv) (iv)injection 1 hour to 7 hrs (hrs (hours)) [2]. Experimental Results: Plasma insulin concentrations were consistently increased compared to vehicle-injected rats. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, weighing 300 to 350 g, with plasma glucose concentration maintained at 11 mM [2]. Doses: 0.5, 5 or 50 pmol/min/kg. Route of Administration: intravenously (iv) (iv)(iv) during the second hour of a 2-hour 11 mmol/L hyperglycemic clamp. Experimental Results: Produced dose-related potentiation of glucose-stimulated increases in plasma insulin concentrations and increases in glucose infusion rates. |
| References |
[1]. Sarrauste de Menthiere, C. et al. Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. European journal of medicinal chemistry 39, 473-480, doi:10.1016/j.ejmech.2004.02.002 (2004).
[2]. Hargrove DM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995 Sep;44(9):1231-7. |
| CAS # |
1450806-98-0
|
|---|---|
| Related CAS # |
GLP-1(7-37);106612-94-6
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~14.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 12.5 mg/mL (3.66 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
